EORTC CLTF 2021 | DMF therapy for CTCL
Jan P. Nicolay
• 15 Oct 2021
Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, discusses the use of dimethyl fumarate (DMF), an NF-kappa-B inhibitor, in cutaneous T-cell lymphoma (CTCL). Dr Nicolay reports that DMF demonstrated the ability to selectively kill cancer cells in the pre-clinical setting and was then explored in the Phase II DMF-CTCL (NCT02546440) trial, which reported promising results with mild side effects. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
